Molecular-targeted therapies were received by four of nine (44%) patients with KRAS wildtype mPDAC, which included afatinib (four patients) and post-afatinib administration of erlotinib (one patient; Fig. 1a), and were administered to patients based on an oncogenic fusion detected in their tumor. This evidence concerns the gene KRAS and neoplasm.